Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now full pipeline

Anemia: full-pipeline trial registry

14 of 74 indexed Anemia trials are currently recruiting.

Corpus placement: #183 of 28,707 conditions by registered trial count.

74 US clinical trials · 14 currently recruiting · #183 of 28,707 conditions by registered trial count

Anemia: 74 US clinical trials tracked, 14 recruiting.

Anemia is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Akebia Therapeutics, running 5 of these trials.

Enrollment posture brief

Registry condition anemia

OPEN 14 | RECR 19% | LATE 26 | EARLY 25 | RANK #183 | SPON 5

Nearest open-share peer: Colonoscopy (19% recruiting · 21 trials)

Chronic Kidney Diseases62.2%Anatomic Stage II Breast Can54.1%Chronic Myelomonocytic Leuke40.5%Anemia (this)19%HIV Infection12.2%
Open-enrollment share among volume-matched conditions near Anemia

Anemia lists 14 open slots (19% of 74 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anemia is recruiting below its size-band peers.

    14 of 74 indexed trials (18.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Anemia trials is spread across many organizations.

    Akebia Therapeutics accounts for 5 of 74 trials (6.8%). 54 distinct sponsors appear on at least one study for this condition label.

  3. Typical Anemia enrolment sits around 161 participants.

    Median target enrolment is 161 among the 73 trials that report a genuine target (sentinel values excluded). 27 of those (37%) plan for fewer than 100 participants.

  4. Anemia research is mostly interventional.

    69 interventional and 5 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 219Phase 320Phase 46

Open and recent trials

74 total, page 1 of 2

RECRUITING 900 participants

Diamond Blackfan Anemia Registry (DBAR)

Northwell Health

NCT00106015

RECRUITING NA 688 participants

Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia

The University of Texas Health Science Center, Houston

NCT05750654

RECRUITING NA 450 participants

A New Combination of Evidence-Based Interventions to Improve Primary Care Diagnostic Safety and Efficiency

The University of Texas Health Science Center, Houston

NCT05735314

RECRUITING Phase 3 300 participants

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Takeda

NCT07422480

RECRUITING Phase 2 300 participants

Choline and Iron Deficiency

University of Minnesota

NCT06527391

RECRUITING NA 275 participants

Kids With Iron Deficiency and Scoliosis

Columbia University

NCT06042699

RECRUITING Phase 1 150 participants

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Disc Medicine

NCT05320198

RECRUITING Phase 2 125 participants

129Xe MRI Cardiopulmonary

Bastiaan Driehuys

NCT06038630

RECRUITING Phase 4 120 participants

Iron Deficiency Anemia (IDA) and the Brain

Children's Hospital Los Angeles

NCT05929729

RECRUITING Phase 2 70 participants

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

NCT05732961

RECRUITING Phase 2 50 participants

Luspatercept for Clonal Cytopenias of Uncertain Significance

Weill Medical College of Cornell University

NCT06788691

RECRUITING Phase 2 40 participants

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

NCT07025512

RECRUITING Phase 2 34 participants

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Fox Chase Cancer Center

NCT05800600

RECRUITING Phase 2 21 participants

Study of DISC-0974-201 in Participants With IBD and Anemia

Disc Medicine

NCT07368972

ACTIVE NOT RECRUITING NA 2,000 participants

Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia

Brigham and Women's Hospital

NCT01632761

ACTIVE NOT RECRUITING Phase 3 692 participants

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Cerus Corporation

NCT03037164

ACTIVE NOT RECRUITING Phase 3 529 participants

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT02048813

ACTIVE NOT RECRUITING 324 participants

RBC Irradiation, Anemia and Gut Injury

Emory University

NCT02741648

ACTIVE NOT RECRUITING Phase 3 313 participants

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Celgene

NCT04717414

ACTIVE NOT RECRUITING Phase 3 247 participants

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

NCT00843882

ACTIVE NOT RECRUITING Phase 1 84 participants

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Incyte Corporation

NCT04455841

ACTIVE NOT RECRUITING Phase 2 70 participants

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Cure HHT

NCT03850964

ACTIVE NOT RECRUITING NA 61 participants

The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females

Nutraceuticals Research Institute

NCT07199244

COMPLETED Phase 3 3,554 participants

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Akebia Therapeutics

NCT02892149

COMPLETED Phase 3 2,781 participants

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

AstraZeneca

NCT02174627

COMPLETED Phase 3 2,018 participants

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

American Regent

NCT00548860

COMPLETED NA 1,824 participants

Transfusion of Prematures Trial

NICHD Neonatal Research Network

NCT01702805

COMPLETED NA 1,763 participants

Helen Keller International's Enhanced-Homestead Food Production Program in Burkina Faso

International Food Policy Research Institute

NCT01825226

COMPLETED Phase 3 1,751 participants

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Akebia Therapeutics

NCT02648347

COMPLETED NA 1,543 participants

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

University of Utah

NCT05634005

COMPLETED Phase 3 803 participants

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Affymax

NCT00597753

COMPLETED Phase 3 594 participants

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

American Regent

NCT00740246

COMPLETED Phase 3 502 participants

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Mayo Clinic

NCT00661999

COMPLETED NA 447 participants

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation

Masimo Corporation

NCT02930850

COMPLETED Phase 3 435 participants

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Sandoz

NCT01693029

COMPLETED Phase 3 430 participants

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00440466

COMPLETED NA 400 participants

Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors

Medical College of Wisconsin

NCT00772083

COMPLETED Phase 3 324 participants

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Hoffmann-La Roche

NCT00081471

COMPLETED Phase 3 319 participants

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Akebia Therapeutics

NCT04313153

COMPLETED Phase 3 282 participants

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Eastern Cooperative Oncology Group

NCT00060398

COMPLETED Phase 3 275 participants

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Memorial Sloan Kettering Cancer Center

NCT00003341

COMPLETED NA 254 participants

Frozen Red Blood Cell Transfusions in Trauma Patients

Oregon Health and Science University

NCT01038557

COMPLETED Phase 4 219 participants

Prevention of Iron Deficiency in Breastfed Infants

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT01444261

COMPLETED Phase 2 210 participants

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Akebia Therapeutics

NCT01906489

COMPLETED NA 197 participants

Iron Depletion and Replacement in Blood Donors

Memorial Blood Centers, Minnesota

NCT01752413

COMPLETED Phase 3 184 participants

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

Takeda

NCT01478971

COMPLETED Phase 1 174 participants

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

AMAG Pharmaceuticals

NCT00360425

COMPLETED Phase 4 161 participants

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

USRC Kidney Research

NCT05951192

COMPLETED Phase 2 150 participants

Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants

The University of Texas Health Science Center, Houston

NCT01224236

COMPLETED NA 143 participants

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026

Masimo Corporation

NCT03610269

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 19
Phase 3 20
Phase 4 6

Named interventions

Most-linked intervention names on Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Laboratory Biomarker Analysis Other
4 trials
Darbepoetin alfa Drug
3 trials
epoetin alfa Biological
3 trials
Vadadustat Drug
3 trials
AKB-6548 Drug
2 trials
Venofer Drug
2 trials
Epoetin Alfa Drug
2 trials

US sites by state

Facility locations filed on Anemia trials. A trial with sites in several states counts in each.

California 29 trials
Texas 22 trials
New York 15 trials
Florida 14 trials
Pennsylvania 11 trials
Georgia 11 trials
Missouri 10 trials
Arizona 10 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anemia page

74 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anemia condition card totals 74 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.